Navigation Links
Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
Date:7/31/2013

St. Louis, Missouri (PRWEB) July 31, 2013

Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for patients with rare and special unmet medical needs for over 30 years. As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B. "Gallus is delighted to partner with Genzyme in bringing this therapy to patients in need," said Mark Bamforth, Gallus’ CEO and President. "We are confident that our deep process development expertise and over ten years of commercial, perfusion-based biomanufacturing for global markets using proprietary, flexible stainless steel bioreactors will result in successful delivery of this therapeutic molecule to advance Genzyme’s clinical program."

Niemann-Pick type B is caused by a deficiency of an enzyme called acid sphingomyelinase, which is required for the normal turnover of sphingomyelin, a major lipid of cell membranes. The enzyme deficiency causes sphingomyelin to accumulate in patients and leads to enlargement of the liver and spleen, lung disease, low blood cell counts and in some cases a shortened lifespan.

About Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Missouri, was established in 2010 and acquired a world class commercial biopharmaceutical manufacturing facility from Johnson & Johnson’s Centocor division in 2011 and has grown its workforce by over 50% since then. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected and approved by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services, visit http://www.gallusbiopharma.com or email info(at)gallusbiopharma(dot)com.

Genzyme® is the registered trademark of Genzyme Corporation. All rights reserved.

For more information:
Contact: Claire Ruzicka
Title: Sr. Marketing Manager
Gallus BioPharmaceuticals, LLC
4766 LaGuardia Drive
St. Louis, MO 63134-3117
USA
Telephone: +1 314-733-3814
Email: claire.ruzicka(at)gallusbiopharma(dot)com

Read the full story at http://www.prweb.com/releases/2013/7/prweb10981911.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
2. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
7. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
10. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
11. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The AMA is happy to announce that $48,000 ... the nation. The scholarships are created through funds donated by model aviation organizations and ... set by the AMA Scholarship Committee, which is made up of model aviation pilots ...
(Date:4/21/2017)... ... 21, 2017 , ... Frederick Innovative Technology Center, Inc. (FITCI), ... businesses, recently earned a $77,518 grant from the Rural Maryland Council (RMC) to ... is Frederick’s first incubator. A non-profit corporation, FITCI is a public-private partnership of ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... announced their strategic partnership to offer a full spectrum of digital security goods ... suite of biometric products and the ground-breaking proactive cybersecurity services and products through ...
(Date:4/20/2017)... ... 20, 2017 , ... USDM Life Sciences , the leading risk management, ... is pleased to announce Holger Braemer as Vice President of its Europe ... in Germany. , Braemer is an integral part of USDM’s expansion of services ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):